Evidence map›Paper›PMID 36558056›Full record

ArticleMolecules (Basel, Switzerland)2022

Enzymatic Synthesis of Vancomycin-Modified DNA.

Chiara Figazzolo, Frédéric Bonhomme, Saidbakhrom Saidjalolov, Mélanie Ethève-Quelquejeu, Marcel Hollenstein

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Antibiotics and Bacterial Resistance-A Short Story of an Endless Arms Race.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Chiara FigazzoloInstitut Pasteur, Université de Paris Cité, CNRS UMR3523, Department of Structural Biology and Chemistry, Laboratory for Bioorganic Chemistry of Nucleic Acids, 28, rue du Docteur Roux, CEDEX 15, 75724 Paris, France.
Frédéric BonhommeInstitut Pasteur, Université de Paris Cité, Department of Structural Biology and Chemistry, Unité de Chimie Biologique Epigénétique, UMR CNRS 3523, 28 rue du Docteur Roux, CEDEX 15, 75724 Paris, France.ORCID 0000-0001-6797-289X
Saidbakhrom SaidjalolovUniversité Paris Cité, CNRS, Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, 75006 Paris, France.
Mélanie Ethève-QuelquejeuUniversité Paris Cité, CNRS, Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, 75006 Paris, France.
Marcel HollensteinInstitut Pasteur, Université de Paris Cité, CNRS UMR3523, Department of Structural Biology and Chemistry, Laboratory for Bioorganic Chemistry of Nucleic Acids, 28, rue du Docteur Roux, CEDEX 15, 75724 Paris, France.ORCID 0000-0003-0263-9206
Centre National de la Recherche Scientifique · FR

Funding

Ecole Doctorale Frontières de l'Innovation en Recherche et Education-Programme Bettencourt PhD fellowshipInstitut Pasteur research fundingPasteur-Paris University (PPU) International Ph.D. Program PIA/ANR-16-CONV-0005
6 · The paper itself

Abstract

Many potent antibiotics fail to treat bacterial infections due to emergence of drug-resistant strains. This surge of antimicrobial resistance (AMR) calls in for the development of alternative strategies and methods for the development of drugs with restored bactericidal activities. In this context, we surmised that identifying aptamers using nucleotides connected to antibiotics will lead to chemically modified aptameric species capable of restoring the original binding activity of the drugs and hence produce active antibiotic species that could be used to combat AMR. Here, we report the synthesis of a modified nucleoside triphosphate equipped with a vancomycin moiety on the nucleobase. We demonstrate that this nucleotide analogue is suitable for polymerase-mediated synthesis of modified DNA and, importantly, highlight its compatibility with the SELEX methodology. These results pave the way for bacterial-SELEX for the identification of vancomycin-modified aptamers.

Indexed as

Aptamers, NucleotideVancomycinAnti-Bacterial AgentsDNADNA-Directed DNA PolymeraseNucleotidesOligonucleotidesSELEX Aptamer TechniqueAnti-Bacterial AgentsAptamers, NucleotideDNADNA-Directed DNA PolymeraseNucleotidesOligonucleotidesVancomycinantimicrobial resistanceDNA polymerasesmodified nucleic acidsnucleoside triphosphatesprimer extension reactionsSELEX

Identifiers

PMID36558056
PMCPMC9782525
OpenAlexW4311788898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.